Argipressin (Vasopressin)
(Synonyms: 精氨加压素; Arg8-vasopressin; AVP) 目录号 : GC30764
精氨酸加压素作为调节血浆渗透压和血容量/血压的重要激素，一直被用于治疗感染性休克和失代偿性肝硬化。
Cas No.:113-79-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Arginine-vasopressin, as an important hormone in the regulation of plasma osmolality and blood volume/pressure, always is used in the treatment of septic shock and decompensated cirrhosis.[1]
In vitro experiment it shown that treatment with 5-10 μM argipressin (vasopressin) in RN46A cells decreased RN46A proliferation, while 10 μM argipressin (vasopressin) decreased the number of cells extending neurites. [2] In vitro, treatment with 0.1 μM and 1 μM. argipressin (vasopressin)in PV cardiomyocytes, there had a faster dose dependent beating rate than control PV cardiomyocytes by 4 and 37% respectively. [3] In vitro, Arginine vasopressin (10-12M-10-6M) can induce markedly concentration-dependent increases of insulin release from both rodent and human beta-cells, as well as mouse islets.[4] Moreover, treatment with 100 pM to 1 μM Arginine-vasopressin in the non-neuronal cells evoked [Ca2+](i) responses and had concentration-dependent responses increased with days in vitro in culture, reaching a maximum amplitude after 4-5 day. [5]
In vivo efficacy test it exhibited that argipressin (vasopressin) shown antinociception in the hot-plate test after intracerebroventricular injection (0.5 ug) and in the acetic acid abdominal constriction test after intraperitoneal injection (0.1 mg/kg).[6] In vivo experiment it demonstrated that treatment with 0.5 u/kg arginine vasopressin intravenously significantly increased the levels of IL-6 mRNA in rat hearts with the maximum level occurred at 6 h.[7]
References:
[1] Wagener G, Bakker J. Vasopressin in cirrhosis and sepsis: physiology and clinical implications. Minerva Anestesiol. 2015 Dec;81(12):1377-83. Epub 2014 Nov 11.
[2] Marinova Z, et al. Effects of oxytocin and Argipressin (Vasopressin) on the proliferation and differentiation of a serotonergic cell line. J Neural Transm (Vienna). 2018 Jan;125(1):103-106.
[3] Huang JH, et al. Argipressin (Vasopressin) modulates electrical activity and calcium homeostasis in pulmonary vein cardiomyocytes. J Biomed Sci. 2019 Sep 17;26(1):71.
[4] Mohan S, et al. Vasopressin receptors in islets enhance glucose tolerance, pancreatic beta-cell secretory function, proliferation and survival. Biochimie. 2019 Mar;158:191-198.
[5] Moriya T, et al. Vasopressin-induced intracellular Ca2? concentration responses in non-neuronal cells of the rat dorsal root ganglion. Brain Res. 2012 Nov 5;1483:1-12.
[6] Hart SL, Oluyomi AO. Vasopressin and stress-induced antinociception in the mouse. Br J Pharmacol. 1990 Feb;99(2):243-6.
[7] Sun SZ, et al. β-Arrestin 2 mediates Argipressin (Vasopressin)-induced IL-6 induction via the ERK1/2-NF-κB signal pathway in murine hearts. Acta Pharmacol Sin. 2020 Feb;41(2):198-207.
精氨酸加压素作为调节血浆渗透压和血容量/血压的重要激素,一直被用于治疗感染性休克和失代偿性肝硬化。[1]
体外实验表明,用 5-10 μM argipressin（血管加压素）处理 RN46A 细胞会降低 RN46A 的增殖,而 10 μM argipressin（血管加压素）会减少延伸轴突的细胞数量。 [2] 在体外,用 0.1 μM 和 1 μM 处理。 PV 心肌细胞中的 argipressin（血管加压素）,其剂量依赖性搏动率比对照 PV 心肌细胞分别快 4% 和 37%。 [3] 在体外,精氨酸加压素 (10-12M-10-6M) 可显着增加胰岛素释放的浓度依赖性来自啮齿动物和人类 β 细胞以及小鼠胰岛。[4] 此外,在非神经元细胞中用 100 pM 至 1 μM 精氨酸加压素处理可诱发 [Ca2+ ](i) 反应和浓度依赖性反应随着体外培养天数的增加而增加,在 4-5 天后达到最大幅度。 [5]
体内药效试验表明,argipressin（血管加压素）在侧脑室注射（0.5 ug）后的热板试验和腹腔注射（0.1 mg/kg）后的醋酸缩腹试验中均表现出镇痛作用。 [6] 体内实验表明,静脉注射0.5 u/kg精氨酸加压素可显着提高大鼠心脏IL-6 mRNA水平,并在6 h时达到最大值。[7]
| Cell experiment [1]: | |
|
Cell lines |
PV cardiomyocytes |
|
Preparation Method |
For the measurement of SR Ca2+ leak, PV cardiomyocytes were incubated with argipressin (vasopressin)(1 µM) or Argipressin (Vasopressin)(1 µM) plus KN-93 (a Ca2+/calmodulin-dependent protein kinase II, CaMKII inhibitor, 1 µM) for 4~6 h before experiments. |
|
Reaction Conditions |
1 µM; 4~6 h |
|
Applications |
Spontaneous Ca2+ transients in argipressin (vasopressin) (1 µM)-treated PV cardiomyocytes were smaller than those in the control by 67%. Argipressin (Vasopressin)(1 µM)-treated PV cardiomyocytes had greater Ca2+ leak than the control, which was attenuated by the presence of KN-93 (1 µM). |
| Animal experiment [2]: | |
|
Animal models |
Rats |
|
Dosage form |
1.0 or 5.0 ug/kg; s.c. |
|
Preparation method |
Rats were injected with a single subcutaneous dose of either saline, argipressin (vasopressin) (1.0 or 5.0 ug/kg), or an argipressin (vasopressin) analog with only weak endocrinological activity, des-gly-argipressin vasopressin ( 1.0, 5.0 or 10.0 ug/kg). Additional extinction trials were conducted at 2, 4, 6 and 8 h post-injection. |
|
Applications |
Argipressin (Vasopressin) potentiated this radial maze extinction behavior while DG-AVP produced behavioral results directionally opposite to those predicted by a memory facilitation hypothesis. In a subsequent experiment, vasopressin had no effects on unconditioned locomotor activity measured 2 and 4 h post-injection. |
|
References: [1] Huang JH, et al. Argipressin (Vasopressin) modulates electrical activity and calcium homeostasis in pulmonary vein cardiomyocytes. J Biomed Sci. 2019 Sep 17;26(1):71. [2] Packard MG, et al. Effects of peripherally injected vasopressin and des-glycinamide vasopressin on the extinction of a spatial learning task in rats. Regul Pept. 1985 May;11(1):51-63. |
|
| Cas No. | 113-79-1 | SDF | |
| 别名 | 精氨加压素; Arg8-vasopressin; AVP | ||
| Canonical SMILES | Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Disulfide bridge: Cys1-Cys6) | ||
| 分子式 | C46H65N15O12S2 | 分子量 | 1084.23 |
| 溶解度 | Water : ≥ 360 mg/mL (332.03 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.9223 mL | 4.6116 mL | 9.2231 mL |
| 5 mM | 0.1845 mL | 0.9223 mL | 1.8446 mL |
| 10 mM | 0.0922 mL | 0.4612 mL | 0.9223 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet